Home / Health / Breakthrough Blood Test for Alzheimer's Now FDA Approved
Breakthrough Blood Test for Alzheimer's Now FDA Approved
4 Sep
Summary
- FDA clears new blood test for Alzheimer's diagnosis.
- PrecivityAD2 test available later this year for adults 40+.
- Test aids diagnosis, complementing clinical evaluation.
The Food and Drug Administration (FDA) has granted clearance for a new blood test, PrecivityAD2, aimed at aiding in the diagnosis of Alzheimer's disease. This test is expected to become available later this year. It is intended for individuals aged 40 and older who are experiencing symptoms of cognitive impairment and are undergoing assessment for Alzheimer's.
The PrecivityAD2 test is designed to detect brain amyloid plaques, a key indicator associated with Alzheimer's disease. Clinical validation studies have shown high predictive values for both positive and negative results. This clearance marks a watershed moment for diagnostic tools, potentially simplifying the diagnostic pathway for patients facing memory concerns.
This new blood test offers a less invasive and potentially more timely alternative to methods like PET scans. By providing answers about amyloid plaques, it can help patients receive a diagnosis and begin treatment sooner, which is critical for a progressive disease like Alzheimer's. Alzheimer's disease accounts for a significant majority of dementia cases, with millions affected in the United States alone.
